The Pharmaceutical Journal
Vol 276 No 7401 p580
20 May 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Age-related macular degeneration treatment launched

Patients with neovascular (wet) age-related macular degeneration (AMD) — a chronic condition causing progessive loss of central vision — may obtain benefit from a new drug, pegaptanib (Macugen), launched by Pfizer. Pegaptanib binds to and inhibits the activity of extracellular vascular endothelial growth factor, a protein responsible for processes that are thought to contribute to the wet form of AMD. The drug is administered by intravitreal injection every six weeks.


Notice-board p588